natgillin/translations-raw huggingface dataset:
The majority of dyspnoea adverse reactions were non-serious ( &lt; 5% of subjects had grade ≥ 3 events), resolved, rarely resulted in treatment discontinuation, and had an onset early in the course of study ( &lt; 3 cycles).
Većina nuspojava dispneje nije bila ozbiljna ( &lt; 5% ispitanika imalo je događaj 3. ili višeg stupnja), povukle su se i rijetko su rezultirale prekidom liječenja, a javljale su se rano u tijeku ispitivanja ( &lt; 3 ciklusa).
The majority of IRRs were mild or moderate in intensity and &lt; 1% resulted in discontinuation of study treatment.
Većina RPI bilo je blagog do umjerenog intenziteta, a &lt; 1% reakcija rezultiralo je prekidom ispitivanog liječenja.
The majority of patients (58%) had LDL- cholesterol &gt; 190 mg/dl at study entry, and 24% of patients with LDL-cholesterol &gt; 190 mg/dl were on lipid lowering medicinal products.
Većina bolesnika (58%) imala je LDL kolesterol &gt; 190 mg/dl pri ulasku u ispitivanje, a 24% bolesnika s LDL kolesterolom &gt; 190 mg/dl uzimalo je lijekove za snižavanje razine lipida.
The majority of patients in this study had a baseline HbA1c of &gt; 8 % (see table 3).
Većina bolesnika u tom ispitivanju imala je početnu vrijednost HbA1c &gt; 8% (vidjeti tablicu 3).
The majority of patients with a baseline eGFR 45 mL/min/1.73 m2 to &lt; 60 mL/min/1.73 m2 were on insulin and/or a sulphonylurea (85% [614/721]).
Većina bolesnika s početnom vrijednošću eGFR 45 mL/min/1,73 m2 do &lt; 60 mL/min/1,73 m2 bili su na inzulinu i/ili sulfonilureji (85% [614/721]).
The majority of patients with elevations had hepatic transaminases that were &lt; 3 times the upper limit of normal (ULN).
Većina bolesnika s povišenim jetrenim transaminazama imala je razine &lt; 3 puta od gornje granice normale (GGN).
The majority of the patients showed sustained reversal of dabigatran plasma concentrations up to 12 hours ( &gt; 90%).
Većina bolesnika pokazala je održano poništenje plazmatskih koncentracija dabigatrana do 12 sati ( &gt; 90%).
The majority of treatment emergent adverse reactions were reported in &lt; 3% of subjects in any treatment group.
Većina nuspojava tijekom liječenja zabilježena je u &lt; 3% ispitanika svake ispitivane skupine.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove. &gt;
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. &gt;
Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
The maternal NOAEL was 10 mg/kg/day, and the developmental NOAEL was &lt; 10 mg/kg/day (AUC24h was 418 ng•h/mL on Gestation Day 19 at this lowest dose tested, which was similar to that obtained from a 4 mg clinical dose).
NOAEL majki bio je 10 mg/kg na dan, a razvojni NOAEL iznosio je &lt; 10 mg/kg na dan (AUC24h je bio 418 ng•h/ml 19. dana gestacije pri ovoj najnižoj ispitanoj dozi, što je bilo slično onome koji se dobio pri kliničkoj dozi od 4 mg).
The maximally tolerated pazopanib dose (MTD) in patients with moderate hepatic impairment (defined as an elevation of bilirubin &gt; 1.5 x to 3 x ULN regardless of the ALT values) was 200 mg once daily.
Najveća podnošljiva doza pazopaniba u bolesnika s umjerenim oštećenjem jetrene funkcije (definirano kao povećanje bilirubina &gt; 1,5 x do 3 x GGN neovisno o vrijednostima ALT-a) je 200 mg jednom dnevno.
The maximum daily melphalan dose is 20 mg in patients &gt; 75 years of age (see Table 1).
Maksimalna dnevna doza melfalana je 20 mg u bolesnika starijih od 75 godina (vidjeti tablicu 1).
The maximum toxicity of diarrhoea was Grade 1 or 2 in 89% of patients, Grade 3 in 11% of patients; one patient ( &lt; 1%) experienced a Grade 4 event.
Maksimalna toksičnost proljeva bila je 1. ili 2. stupnja u 89% bolesnika, 3. stupnja u 11% bolesnika, a jedan bolesnik ( &lt; 1%) imao je događaj 4. stupnja.
The maximum volume which can be withdrawn at one time is 5 ml (equivalent to 500 mg tipranavir), which is the maximum single dose for a child with BSA &gt; 1.33 m2.
Maksimalni volumen koji se može izvući u jednom trenutku je 5 ml (ekvivalentno 500 mg tipranavira), što je maksimalna pojedinačna doza za dijete s površinom tijela &gt; 1,33 m2.
The maximum volume you can withdraw at one time is 5 ml (equivalent to 500 mg tipranavir), which is the maximum single dose for a child with BSA (Calculated body surface area) &gt; 1.33 m2
Maksimalni volumen koji možete izvući u jednom trenutku je 5 ml (odgovara 500 mg tipranavira), što je maksimalna jednostruka doza za dijete s površinom tijela &gt; 1,33 m2
The mean (±SD) serum adalimumab trough concentrations achieved at Week 4 were 15.7 ± 6.6 g/ml for patients ≥ 40 kg (160/80 mg) and 10.6 ± 6.1 g/ml for patients &lt; 40 kg (80/40 mg).
Srednje vrijednosti (±SD) najnižih koncentracija adalimumaba u serumu u 4. tjednu bile su 15,7 ± 6,6 g/ml u bolesnika tjelesne težine ≥ 40 kg (160/80 mg) i 10,6 ± 6,1 g/ml u bolesnika tjelesne težine &lt; 40 kg (80/40 mg).
The mean (±SD) serum adalimumab trough concentrations achieved at Week 4 were 15.7±6.6 g/mL for patients ≥ 40 kg (160/80 mg) and 10.6±6.1 g/mL for patients &lt; 40 kg (80/40 mg).
Srednje vrijednosti (±SD) najnižih koncentracija adalimumaba u serumu u 4. tjednu bile su 15,7 ± 6,6 g/ml u bolesnika tjelesne težine ≥ 40 kg (160/80 mg) i 10,6 ± 6,1 g/ml u bolesnika tjelesne težine &lt; 40 kg (80/40 mg).
The mean (±SD) serum adalimumab trough concentrations achieved at Week 4 were 15.7±6.6 g/mL for patients  40 kg (160/80 mg) and 10.6±6.1 g/mL for patients &lt; 40 kg (80/40 mg).
Srednje vrijednosti (±SD) najnižih koncentracija adalimumaba u serumu u 4. tjednu bile su 15,7 ± 6,6 g/ml u bolesnika tjelesne težine ≥ 40 kg (160/80 mg) i 10,6 ± 6,1 g/ml u bolesnika tjelesne težine &lt; 40 kg (80/40 mg).
The mean absolute change in BMI from baseline in Trial 1 or Trial 2 at week 24 in Trial 3 was 0.56 kg/m2 (P &lt; 0.0001).
Srednja vrijednost apsolutne promjene indeksa tjelesne mase u odnosu na početnu vrijednost u ispitivanju 1 ili ispitivanju 2 iznosila je u ispitivanju 3 u 24. tjednu 0,56 kg/m2 (P &lt; 0,0001).
The mean AUC for subjects with creatinine clearance &lt; 30 ml/min was approximately 2 - fold higher.
Srednja vrijednost AUC u ispitanika s klirensom kreatinina &lt; 30 ml/min je bila otprilike dvaput veća.
The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p &lt; 0.0001).
Prosječna početna vrijednost krvnog tlaka bila je približno 172/113 mmHg u svakoj skupini, a smanjivanje sistoličkog/dijastoličkog tlaka u sjedećem položaju u pet tjedana iznosilo je 30,8/24,0 mmHg za irbesartan/hidroklorotiazid te 21,1/19,3 mmHg za irbesartan (p &lt; 0,0001).
The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p &lt; 0.0001).
Srednja početna vrijednost krvnog tlaka bila je približno 172/113 mmHg u svakoj skupini, a smanjivanje sistoličkog/dijastoličkog tlaka u sjedećem položaju u pet tjedana iznosilo je 30,8/24,0 mmHg za irbesartan/hidroklorotiazid te 21,1/19,3 mmHg za irbesartan (p &lt; 0,0001).
The mean baseline CD4+ cell count was 427 cells/mm3 (range 0-1,360) and 13% had a CD4+ cell count &lt; 200 cells/mm3.
Srednja početna vrijednost broja CD4+ stanica bila je 427 stanica/mm3 (raspon 0-1360), a 13% imalo je broj CD4+ stanica &lt; 200 stanica/mm3.
The mean baseline CD4+ cell count was 427 cells/mm3 (range 0-1,360) and 13% had CD4+ cell counts &lt; 200 cells/mm3.
Srednja početna vrijednost broja CD4+ stanica bila je 427 stanica/mm3 (raspon 0-1360), a 13% imalo je broj CD4+ stanica &lt; 200 stanica/mm3.
The mean baseline plasma HIV-1 RNA was 4.5 log10 copies/mL (range 1.3-7.0) and 23% of patients had baseline viral loads &gt; 100,000 copies/mL.
Srednja početna vrijednost HIV-1 RNK u plazmi bila je 4,5 log10 kopija/ml (raspon 1,3-7,0), a 23% imalo je početno virusno opterećenje &gt; 100 000 kopija/ml.
The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to tocilizumab 8 mg/kg plus MTX (p &lt; 0.0001) compared with patients who were randomised to placebo plus MTX.
Srednja promjena ukupnog rezultata na Sharp-Genantovoj ljestvici u 104. tjednu u odnosu na početnu razinu bila je znatno manja za bolesnike randomizirane u skupinu koja je primala tocilizumab u dozi od 8 mg/kg u kombinaciji s MTX-om (p &lt; 0,0001) u usporedbi s bolesnicima koji su randomizirani u skupinu koja je primala placebo i MTX.
The mean change in the global health status at week 24, as measured by EORTC QLQ C30 was +12.3 for Jakavi and -3.4 for placebo (p &lt; 0.0001).
Srednja promjena u općem zdravstvenom statusu u 24. tjednu, mjereno pomoću EORTC QLQ C30, bila je +12,3 za Jakavi i -3,4 za placebo (p &lt; 0,0001).
The mean difference in CFA-72h was 26 percentage points greater with Enzepi treatment with a 95% Confidence Interval of (19, 32) and p &lt; 0.001.
Srednja vrijednost razlike u CFA-72 h bila je 26 postotnih točaka veća kod liječenja lijekom Enzepi uz 95%-tni interval pouzdanosti od (19, 32) i p &lt; 0,001.
The mean estimated vorapaxar Cmax and AUC were 35% and 33% higher, respectively, in patients with a body weight of &lt; 60 kg compared to those weighing 60-100 kg.
Srednja procijenjena vrijednost Cmax i AUC-a vorapaksara bila je 35% odnosno 33% veća u bolesnika tjelesne težine &lt; 60 kg u odnosu na one čija je tjelesna težina 60-100 kg.
The mean Ishak score of 2.2 (SD 1.1) at baseline improved (p &lt; 0.0001) to 0.9 (SD 1.0) with a mean change of -1.3 (SD 1.3).
Prosječan Ishak skor od 2,2 (SD 1,1) na početku, poboljšan je (p &lt; 0,0001) na 0,9 (SD 1,0) sa srednjom promjenom od -1,3 (SD 1,3).
The mean ivabradine doses allowing to achieve a 20% HRR were 0.13 ± 0.04 mg/kg bid, 0.10 ± 0.04 mg/kg bid and 4.1 ± 2.2 mg bid in the age subsets [1-3[ years, [3-18[ years and &lt; 40 kg and [3-18[ years and ≥ 40 kg, respectively.
Srednje doze ivabradina koje su omogućile postizanje sniženje broja otkucaja srca za 20% su 0,13 ± 0,04 mg/kg/dan dva puta na dan, 0,10 ± 0,04 mg/kg/dan dva puta na dan i 4,1 ± 2,2 mg dva puta na dan u starosnim podskupinama [1-3[ godine, [3-18[ godina i s &lt; 40 kg te [3-18[ godina i s ≥ 40 kg.
The mean ivabradine doses allowing to achieve a 20% HRR were 0.13 ± 0.04 mg/kg bid, 0.10 ± 0.04 mg/kg bid and 4.1 ± 2.2 mg bid in the age subsets [1-3[ years, [3-18[ years and &lt; 40 kg and [3-18[ years and ≥ 40 kg, respectively.
Srednje doze ivabradina koje su omogućile postizanje sniženje frekvencije srca za 20% su 0,13 ± 0,04 mg/kg dva puta na dan, 0,10 ± 0,04 mg/kg dva puta na dan i 4,1 ± 2,2 mg dva puta na dan u dobnim podskupinama od [1-3[ godine, [3-18[ godina i s &lt; 40 kg, odnosno [3-18[ godina i s ≥ 40 kg.
The mean Knodell necroinflammatory score of 7.6 (SD 2.9) at baseline improved (p &lt; 0.0001) to 1.4 (SD 0.9) with a mean change of -6.3 (SD 2.8).
Prosječan Knodellov nekroinflamatorni skor 7,6 (SD 2,9) na početku, poboljšan je (p &lt; 0,0001) na 1,4 (SD 0,9) sa srednjom promjenom od -6,3 (SD 2,8).
The mean LVEF was 29% and there were 963 (11.4%) patients with a baseline LVEF &gt; 35% and ≤40%.
Srednja LVEF bila je 29% i bilo je 963 (11,4%) bolesnika s početnom LVEF &gt; 35% i ≤40%.
The mean oral clearance was slightly higher for paediatric patients, however the differences were minor in magnitude ( &lt; 20%).
Prosječni oralni klirens bio je nešto viši za pedijatrijske bolesnike, međutim, razlike su bile manjeg reda veličine ( &lt; 20%).
The mean percentage of methylnaltrexone bromide resulting in any RFBM within 4 hours were 28.9% and 30.2% respectively for the once daily and every other day dose groups compared with 9.4% and 9.3% respectively for the corresponding placebo regimen (p &lt; 0.001).
Prosječni postotak metilnaltreksonbromida koji je doveo do pražnjenja crijeva bez primjene dodatnog laksativa, unutar 4 sata iznosio je 28,9% za skupinu koja je uzimala lijek jedanput dnevno, odnosno 30,2% za skupinu koja je uzimala lijek svaki drugi dan u usporedbi s 9,4%, odnosno 9,3% za odgovarajući placebo režim (p &lt; 0,001).
The mean percentage of methylnaltrexone bromide resulting in any RFBM within 4 hours were 28.9% and 30.2% respectively for the once daily and every other day dose groups compared with 9.4% and 9.3% respectively for the corresponding placebo regimen (p &lt; 0.001).
Prosječni postotak metilnaltreksonbromida koji je doveo do pražnjenja crijeva bez primjene dodatnog laksativa, unutar 4 sata iznosio je 28,9% za skupinu koja je uzimala lijek jedanput dnevno, odnosno 30,2% za kupinu koja je uzimala lijek svaki drugi dan u usporedbi s 9,4%, odnosno 9,3% za odgovarajući placebo režim (p &lt; 0,001).
The mean percentage of methylnaltrexone bromide resulting in any RFBM within 4 hours were 28.9% and 30.2% respectively for the once daily and every other day dose groups compared with 9.4% and 9.3% respectively for the corresponding placebo regimen for daily and every other day dosing (p &lt; 0.001) during the double blind phase.
Prosječni postotak metilnaltreksonbromida koji je doveo do pražnjenja crijeva bez primjene dodatnog laksativa, unutar 4 sata iznosio je 28,9% za skupinu koja je uzimala lijek jedanput dnevno, odnosno 30,2% za skupinu koja je uzimala lijek svaki drugi dan u usporedbi s 9,4%, odnosno 9,3% za odgovarajući placebo režim (p &lt; 0,001).
The mean postural changes in systolic and diastolic blood pressure over time were small ( &lt; 10 mmHg) and returned towards baseline beyond 2 hours.
Srednje vrijednosti posturalne promjene sistoličkog i dijastoličkog krvnog tlaka tijekom vremena su bile male ( &lt; 10 mmHg) i vratile su se prema početnim vrijednostima nakon 2 sata.
The mean postural changes in systolic and diastolic blood pressure over time were small ( &lt; 10 mmHg) and returned towards baseline beyond 2 hours.
Srednje vrijednosti posturalnih promjena sistoličkog i dijastoličkog krvnog tlaka tijekom vremena su bile male ( &lt; 10 mmHg) i vratile su se prema početnim vrijednostima nakon 2 sata.
The mean pre-dose FEV1 (average of the values taken at -45 and -15 minutes prior to the morning dose of study medication) was statistically significant in favour of Ultibro Breezhaler at week 26 compared to fluticasone/salmeterol (100 ml, p &lt; 0.001), at week 52 compared to placebo (189 ml, p &lt; 0.001) and at all visits up to week 64 compared to glycopyrronium (70-80 ml, p &lt; 0.001) and tiotropium (60-70 ml, p &lt; 0.001).
Srednji FEV1 prije doze (prosjek vrijednosti izmjerenih -45 i -15 minuta prije jutarnje doze ispitivanog lijeka) bio je statistički značajan u korist Ultibro Breezhalera u 26 tjednu u usporedbi s flutikazonom/salmeterolom (100 ml, p &lt; 0,001), u 52 tjednu u usporedbi s placebom (189 ml, p &lt; 0,001) i na svim posjetima do 64. tjedna u usporedbi s glikopironijem (70-80 ml, p &lt; 0,001) i tiotropijem (60-70 ml, p &lt; 0,001).
The mean pre-dose FEV1 (average of the values taken at -45 and -15 minutes prior to the morning dose of study medication) was statistically significant in favour of Ulunar Breezhaler at week 26 compared to fluticasone/salmeterol (100 ml, p &lt; 0.001), at week 52 compared to placebo (189 ml, p &lt; 0.001) and at all visits up to week 64 compared to glycopyrronium (70-80 ml, p &lt; 0.001) and tiotropium (60-70 ml, p &lt; 0.001).
Srednji FEV1 prije doze (prosjek vrijednosti izmjerenih -45 i -15 minuta prije jutarnje doze ispitivanog lijeka) bio je statistički značajan u korist Ulunar Breezhalera u 26 tjednu u usporedbi s flutikazonom/salmeterolom (100 ml, p &lt; 0,001), u 52 tjednu u usporedbi s placebom (189 ml, p &lt; 0,001) i na svim posjetima do 64. tjedna u usporedbi s glikopironijem (70-80 ml, p &lt; 0,001) i tiotropijem (60-70 ml, p &lt; 0,001).
The mean pre-dose FEV1 (average of the values taken at -45 and -15 minutes prior to the morning dose of study medication) was statistically significant in favour of Xoterna Breezhaler at week 26 compared to fluticasone/salmeterol (100 ml, p &lt; 0.001), at week 52 compared to placebo (189 ml, p &lt; 0.001) and at all visits up to week 64 compared to glycopyrronium (70-80 ml, p &lt; 0.001) and tiotropium (60-70 ml, p &lt; 0.001).
Srednji FEV1 prije doze (prosjek vrijednosti izmjerenih -45 i -15 minuta prije jutarnje doze ispitivanog lijeka) bio je statistički značajan u korist Xoterna Breezhalera u 26 tjednu u usporedbi s flutikazonom/salmeterolom (100 ml, p &lt; 0,001), u 52 tjednu u usporedbi s placebom (189 ml, p &lt; 0,001) i na svim posjetima do 64. tjedna u usporedbi s glikopironijem (70-80 ml, p &lt; 0,001) i tiotropijem (60-70 ml, p &lt; 0,001).
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, predominantly by renal clearance ( &gt; 70%) via the organic cationic transport system.
Srednja vrijednost sistemskog klirensa lamivudina iznosi oko 0,32 l/h/kg, najvećim dijelom bubrežnim klirensom ( &gt; 70%) preko organskog kationskog transportnog sistema.
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance ( &gt; 70 %) via the organic cationic transport system.
Srednja vrijednost sistemskog klirensa lamivudina iznosi oko 0,32 l/h/kg, najvećim dijelom bubrežnim klirensom ( &gt; 70%) preko organskog kationskog transportnog sistema.
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance ( &gt; 70 %) via the organic cationic transport system.
Prosječna vrijednost sistemskog klirensa lamivudina iznosi oko 0,32 l/h/kg, s predominantnim bubrežnim klirensom ( &gt; 70%) putem organskog kationskog transportnog sistema.
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance ( &gt; 70%) via the organic cationic transport system.
Prosječna vrijednost sistemskog klirensa lamivudina iznosi oko 0,32 l/h/kg, s predominantnim bubrežnim klirensom ( &gt; 70%) putem organskog kationskog transportnog sistema.
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance ( &gt; 70%) via the organic cationic transport system.
Srednji sistemski klirens lamivudina je približno 0,32 l/h/kg, i odvija se pretežno renalnim klirensom ( &gt; 70%), putem organskog kationskog transportnog sustava.
The median (min-max) renal clearance of adefovir in subjects with normal renal function (Clcr &gt; 80 ml/min) is 211 ml/min (172-316 ml/min), approximately twice calculated creatinine clearance (Cockroft-Gault method).
Medijan (min.-maks.) bubrežnog klirensa adefovira u ispitanika s normalnom bubrežnom funkcijom (Clcr &gt; 80 ml/min) iznosi 211 ml/min (172-316 ml/min), što je približno dvostruka vrijednost izračunatog klirensa kreatinina (Cockroft-Gault metoda).
The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 96 was 0.1 (-0.3, 0.7) in the E/C/F/TAF group and 0.0 (-0.4, 0.5) in the E/C/F/TDF group (p &lt; 0.001 for the difference between treatment groups).
Medijan (Q1, Q3) promjene omjera ukupnog kolesterola i HDL kolesterola od početne vrijednosti do vrijedosti u 96. tjednu bio je 0,1 (-0,3; 0,7) u skupini liječenoj E/C/F/TAF-om i 0,0 (-0,4; 0,5) u skupini liječenoj E/C/F/TDF-om (p &lt; 0,001 za razliku izmeĎu liječenih skupina).
The median age of all patients receiving Odomzo 200 mg was 67 years (59.5% were &gt; 65 years of age), 60.8% were male and 89.9% Caucasian.
Medijan dobi svih bolesnika koji su primali Odomzo 200 mg bio je 67 godina (59,5% imalo je &gt; 65 godina), 60,8% bili su muškarci, a 89,9% bijelci.
The median average weekly dose of ALPROLIX was 59.40 IU/kg (interquartile range, 52.95 to 64.78 IU/kg) for subjects &lt; 6 years of age and 57.78 IU/kg (interquartile range, 51.67 to 65.01 IU/kg) for subjects 6 to &lt; 12 years of age.
Medijan prosječne tjedne doze lijeka ALPROLIX iznosio je 59,40 IU/kg (interkvartilni raspon od 52,95 do 64,78 IU/kg) u ispitanika &lt; 6 godina te 57,78 IU/kg (interkvartilni raspon od 51,67 do 65,01 IU/kg) u ispitanika u dobi od 6 do &lt; 12 godina.
The median dose of thalidomide was 217 mg and &gt; 40% of patients received 9 cycles.
Medijan doze talidomida iznosio je 217 mg i &gt; 40% bolesnika primilo je 9 ciklusa.
The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p &lt; 0.0001, log-rank test).
Medijan odgovora iznosio je 37,7 mjeseci u skupini liječenoj R-CVP-om i 13,5 mjeseci u skupini liječenoj CVP-om (p &lt; 0,0001, log-rang test).
The median duration of Soliris therapy was 16 weeks (range 4 to 70 weeks) for children &lt; 2 years of age (n=5) and 31 weeks (range 19 to 63 weeks) for children 2 to &lt; 12 years of age (n=10).
Medijan trajanja terapije lijekom Soliris iznosio je 16 tjedana (raspon od 4 do 70 tjedana) u djece dobi &lt; 2 godine (n = 5), i 31 tjedan (raspon od 19 do 63 tjedna) u djece u dobi od 2 do &lt; 12 godina (n = 10).
The median EDSS score at baseline was 2.50; 249 patients (22.9%) had an EDSS score › 3.5 at baseline.
Medijan EDSS rezultata na početku liječenja iznosio je 2,50; 249 bolesnika (22,9%) je na početku liječenja imalo EDSS rezultat &gt; 3,5.
The median EDSS score at baseline was 2.50; 298 patients (25.5%) had an EDSS score › 3.5 at baseline.
Medijan EDSS rezultata na početku liječenja iznosio je 2,50: 298 bolesnika (25,5%) je na početku liječenja imalo EDSS rezultat &gt; 3,5.
The median estimated CrCl was 62 mL/min and 66% of all patients had a CrCl &lt; 70 mL/min.
Medijan procijenjenog CrCl iznosio je 62 ml/min, a 66% svih bolesnika imalo je CrCl &lt; 70 ml/min.
The median increase from baseline for these parameters was greater in patients receiving emtricitabine+tenofovir alafenamide compared with patients receiving emtricitabine+tenofovir disoproxil fumarate, both given with elvitegravir+cobicistat as a fixed-dose combination tablet (p &lt; 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides).
Medijan povećanja ovih parametara od početnih vrijednosti bio je veći u bolesnika koji su primali emtricitabin+tenofoviralafenamid u usporedbi s bolesnicima koji su primali emtricitabin+tenofovirdizoproksilfumarat, pri čemu su oba lijeka davana s elvitegravirom+kobicistatom u obliku tablete s fiksnom kombinacijom (p &lt; 0,001 za razliku između liječenih skupina u vrijednostima ukupnog kolesterola, LDL i HDL kolesterola te triglicerida natašte).
The median increase from baseline for those parameters was greater in the Genvoya group compared with the E/C/F/TDF group at Week 96 (p &lt; 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides).
Medijan porasta ovih parametara od početnih vrijednosti bio je veći u skupini liječenoj lijekom Genvoya u usporedbi sa skupinom liječenom E/C/F/TDF u 96. tjednu (p &lt; 0,001 za razliku između liječenih skupina u vrijednostima ukupnog kolesterola, LDL i HDL kolesterola te triglicerida natašte).
The median lifetime cumulative dose of Myocet in combination with CPA to a cardiac event was &gt; 1260 mg/m2, compared to 480 mg/m2 for doxorubicin combination with CPA.
Medijan doživotne kumulativne doze Myoceta u kombinaciji s CPA za srčani događaj iznosio je &gt; 1260 mg/m2 u usporedbi s 480 mg/m2 za doksorubicin u kombinaciji s CPA.